Quince Therapeutics, Inc. Business Combination, Contingent Consideration, Liability, Current
Quince Therapeutics, Inc. (QNCX) had Business Combination, Contingent Consideration, Liability, Current of $0 as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent · last filed 2026-08-14
- 2026-06-30: Business Combination, Contingent Consideration, Liability, Current $0.00.
- 2026-03-31: Business Combination, Contingent Consideration, Liability, Current $0.00.
- 2025-12-31: Business Combination, Contingent Consideration, Liability, Current $12.37M.
- 2024-12-31: Business Combination, Contingent Consideration, Liability, Current $0.00.
| Period end | Business Combination, Contingent Consideration, Liability, Current |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-14 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-11 |
| 2025-12-31 | $12.37M 10-Q · filed 2026-08-14 |
| 2024-12-31 | $0.00 10-K · filed 2026-04-10 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 |
| 2024-06-30 | $5.00M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $4.75M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $4.10M 10-K · filed 2025-03-24 |
| 2022-12-31 | $0.00 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |